Related Experiment Video
Updated: May 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Management of enzalutamide, a new hormonal therapy]
Philippe Beuzeboc1, Marc-Antoine Benderra2, Thibault de La Motte Rouge2
1Institut Curie, 26, rue d'Ulm 75248 Paris cedex 05, France.
Abstract:
Enzalutamide (MDV3100) is a non-steroidal antiandrogen of second generation that has shown efficacy in metastatic castration-resistant prostate cancer (mCRPC). The study AFFIRM demonstrated a statistically significant increase in overall survival among patients who have progressed following a docetaxel chemotherapy. Based on these results, a marketing authorization for enzalutamide has been granted. The enzalutamide has been shown to be generally well tolerated. Other trials are underway to evaluate its earlier use in the management of mCRPC. A pivotal registration phase III study (PREVAIL) is ongoing to investigate the effectiveness of enzalutamide in patients who have not yet received chemotherapy.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi V: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Atherosclerosis III: Management
Nephrotic Syndrome III : Nursing Management
Urinary Tract Infection IV: Nursing Management

